|
2025 Conference Publication Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trialHicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Thomson, R., Burke, A., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. (2025). Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trial. TSANZSRS Annual Scientific meeting 2025, Adelaide, SA Australia, 21-25 March 2025. Richmond, VIC Australia: John Wiley & Sons. |
|
2025 Journal Article The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary diseaseMou, Claire Y., Henderson, Daniel J., Matson, Angela G., Herd, Karen M., Reid, David W., Riddles, Timothy, Johnson, Ellie, McWhinney, Brett, Swenson, Rebecca, Burke, Andrew and Evans, Ieuan E.S. (2025). The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease. European Clinical Respiratory Journal, 12 (1) 2458341, 1-5. doi: 10.1080/20018525.2025.2458341 |
|
2025 Journal Article Evaluating the feasibility, sensitivity, and specificity of next-generation molecular methods for pleural infection diagnosisBell, Peter T., Baird, Timothy, Goddard, John, Olagoke, Olusola S., Burke, Andrew, Subedi, Shradha, Davey, Tiana R., Anderson, James, Sarovich, Derek S. and Price, Erin P. (2025). Evaluating the feasibility, sensitivity, and specificity of next-generation molecular methods for pleural infection diagnosis. Microbiology Spectrum, 13 (2), 1-20. doi: 10.1128/spectrum.01960-24 |
|
2024 Journal Article Imipenem pharmacokinetics/pharmacodynamics in preclinical hollow fiber model, dose-finding in virtual patients, and clinical evidence of efficacy for Mycobacterium abscessus lung diseaseSingh, Sanjay, Gumbo, Tawanda, Wang, Jann-Yuan, Boorgula, Gunavanthi D., Burke, Andrew, Huang, Hung-Ling, McShane, Pamela J., Amaro-Galvez, Rodolfo, Gross, Jane E., Aryal, Santosh, Heysell, Scott K and Srivastava, Shashikant (2024). Imipenem pharmacokinetics/pharmacodynamics in preclinical hollow fiber model, dose-finding in virtual patients, and clinical evidence of efficacy for Mycobacterium abscessus lung disease. The Journal of Infectious Diseases, 231 (6) jiae601, 1-11. doi: 10.1093/infdis/jiae601 |
|
2024 Conference Publication Developing a pharmacovigilance framework for an investigator led, non-commercial international adaptive platform trialRice, Megan, Hicks, Daniel, Jong, Tiffany, Gailer, Nicolas, Joshi, Sri, Stevens, Luke, Lee, Kate, Thomson, Rachel, Burke, Andrew, Grimwood, Keith, Bell, Scott, Clark, Julia and Wainwright, Claire E. (2024). Developing a pharmacovigilance framework for an investigator led, non-commercial international adaptive platform trial. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD, Australia, 2–4 August 2024. Richmond, VIC, Australia: John Wiley & Sons. |
|
2024 Conference Publication Rifabutin induces Elexacaftor metabolism in Mycobacterium abscessus-related pulmonary disease: A case studyMattison, Graeme, Keating, Rebecca, McWhinney, Brett, Connors, Shannon, Swenson, Rebecca, Evans, Ieuan, Burke, Andrew and Burr, Lucy (2024). Rifabutin induces Elexacaftor metabolism in Mycobacterium abscessus-related pulmonary disease: A case study. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD Australia, 2–4 August 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Journal Article New oxazolidinones for tuberculosis: are novel treatments on the horizon?Chen, Ricky Hao, Burke, Andrew, Cho, Jin-Gun, Alffenaar, Jan-Willem and Davies Forsman, Lina (2024). New oxazolidinones for tuberculosis: are novel treatments on the horizon?. Pharmaceutics, 16 (6) 818, 818. doi: 10.3390/pharmaceutics16060818 |
|
2024 Conference Publication Developing a pharmacovigilance framework for an investigator-led, non-commercial platform trial – finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT)Hicks, D., Jong, T., Rice, M., Gailer, N., Joshi, S., Stevens, L., Lee, K., Thomson, R., Burke, A., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2024). Developing a pharmacovigilance framework for an investigator-led, non-commercial platform trial – finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT). 47th European Cystic Fibrosis Conference, Glasgow, United Kingdom, 5-8 June 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s1569-1993(24)00244-3 |
|
2024 Journal Article OPTIMA: an open-label, non-comparative pilot trial of inhaled molgramostim in pulmonary nontuberculous mycobacterial infectionThomson, Rachel M., Loebinger, Michael R., Burke, Andrew J., Morgan, Lucy C., Waterer, Grant W. and Ganslandt, Cecilia (2024). OPTIMA: an open-label, non-comparative pilot trial of inhaled molgramostim in pulmonary nontuberculous mycobacterial infection. Annals of the American Thoracic Society, 21 (4), 568-576. doi: 10.1513/annalsats.202306-532oc |
|
2024 Journal Article Prevalence, risk factors, clinical features, and outcome of Influenza-Associated Pulmonary Aspergillosis (IAPA) in critically ill patients: a systematic review and meta-analysisLu, Lawrence Y., Lee, Hui Min, Burke, Andrew, Li Bassi, Gianluigi, Torres, Antoni, Fraser, John F. and Fanning, Jonathon P. (2024). Prevalence, risk factors, clinical features, and outcome of Influenza-Associated Pulmonary Aspergillosis (IAPA) in critically ill patients: a systematic review and meta-analysis. CHEST, 165 (3), 540-558. doi: 10.1016/j.chest.2023.09.019 |
|
2024 Journal Article A case of severe Mycobacterium thermoresistibile pneumoniaSubramaniam, Selvaraj, Kanhere, Mrudula, Shephard, Lisa, Burke, Andrew, Saxon, Sarah and Geake, James (2024). A case of severe Mycobacterium thermoresistibile pneumonia. Respirology Case Reports, 12 (3) e01308, 1-6. doi: 10.1002/rcr2.1308 |
|
2024 Conference Publication Performance of next generation molecular methods in diagnosing pleural space infectionBaird, T., Bell, P., Goddard, J., Olagoke, O., Burke, A., Subedi, S., Davey, T., Anderson, J., Sarovich, D. and Price, E. (2024). Performance of next generation molecular methods in diagnosing pleural space infection. HOBOKEN: WILEY. |
|
2023 Journal Article Medications and monitoring in treatment of nontuberculous mycobacteria lung diseaseSawka, Alice and Burke, Andrew (2023). Medications and monitoring in treatment of nontuberculous mycobacteria lung disease. Clinics in Chest Medicine, 44 (4), 815-828. doi: 10.1016/j.ccm.2023.06.012 |
|
2023 Journal Article A randomized trial of Nafamostat for Covid-19Morpeth, Susan C., Venkatesh, Balasubramanian, Totterdell, James A., McPhee, Grace M., Mahar, Robert K., Jones, Mark, Bandara, Methma, Barina, Lauren A., Basnet, Bhupendra K., Bowen, Asha C., Burke, Andrew J., Cochrane, Belinda, Denholm, Justin T., Dhungana, Ashesh, Dore, Gregory J., Dotel, Ravindra, Duffy, Eamon, Dummer, Jack, Foo, Hong, Gilbey, Timothy L., Hammond, Naomi E., Hudson, Bernard J., Jha, Vivekanand, Jevaji, Purnima R., John, Oommen, Joshi, Rajesh, Kang, Gagandeep, Kaur, Baldeep, Kim, Seungtaek ... Tong, Steven Y.C. (2023). A randomized trial of Nafamostat for Covid-19. NEJM Evidence, 2 (11), EVIDoa2300132-11. doi: 10.1056/evidoa2300132 |
|
2023 Journal Article In vitro susceptibility testing of imipenem- relebactam and tedizolid against 102 Mycobacterium abscessus isolatesBurke, Andrew, Carter, Robyn, Tolson, Carla, Congdon, Jacob, Duplancic, Christine, Bursle, Evan, Bell, Scott C., Roberts, Jason A. and Thomson, Rachel (2023). In vitro susceptibility testing of imipenem- relebactam and tedizolid against 102 Mycobacterium abscessus isolates. International Journal of Antimicrobial Agents, 62 (4) 106938, 1-6. doi: 10.1016/j.ijantimicag.2023.106938 |
|
2023 Journal Article Pre-XDR congenital tuberculosis in an extremely premature babyBoast, Alison, How, Jeu Ann, Lau, Charis, Sett, Arun, Gilby, Damian, Burke, Andrew, McWhinney, Brett, Wright, Connor, Tramontana, Adrian, Globan, Maria, Denholm, Justin, Graham, Stephen M and Osowicki, Joshua (2023). Pre-XDR congenital tuberculosis in an extremely premature baby. Clinical Infectious Diseases, 78 (1), 149-153. doi: 10.1093/cid/ciad540 |
|
2023 Journal Article A mariner's tale: invasive endotracheal Mycobacterium marinum infectionBell, Peter T., Anderson, James, Coulter, Christopher, Dettrick, Andrew J., Burke, Andrew and Baird, Timothy (2023). A mariner's tale: invasive endotracheal Mycobacterium marinum infection. Respirology Case Reports, 11 (10) e01211, 1-5. doi: 10.1002/rcr2.1211 |
|
2023 Journal Article Mycoplasma hominis and Ureaplasma urealyticum infections in the immediate post-lung transplant period: A case series and literature reviewDivithotewala, Chandima, Sweeney, Emma L., Burke, Andrew, Graves, Bianca, Stewart, Adam, Whiley, David, Heney, Claire, Hopkins, Peter M. and Chambers, Daniel C. (2023). Mycoplasma hominis and Ureaplasma urealyticum infections in the immediate post-lung transplant period: A case series and literature review. Transplant Infectious Disease, 25 (3) e14058, 1-7. doi: 10.1111/tid.14058 |
|
2023 Conference Publication Mycobacterium abscessus: Acquisition and transmission pathwaysRamsay, K., Smith, K., Carter, R., Clayton, M., Burke, A., Wainwright, C., Thomson, R. and Bell, S. (2023). Mycobacterium abscessus: Acquisition and transmission pathways. TSANZSRS 2023 The Australia and New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand (ANZSRS/TSANZ) Annual Scientific Meeting for Leaders in Lung Health and Respiratory Science, Christchurch, New Zealand, 25–28 March 2023. Richmond, VIC Australia: John Wiley and Sons. doi: 10.1111/resp.14459 |
|
2023 Journal Article Nontuberculous Mycobacteria in Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Regulator ModulatorsBurke, Andrew, Thomson, Rachel M., Wainwright, Claire E. and Bell, Scott C. (2023). Nontuberculous Mycobacteria in Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Regulator Modulators. Seminars in Respiratory and Critical Care Medicine, 44 (02), 287-296. doi: 10.1055/s-0042-1759883 |
